News Column

Studies from Laval University Yield New Data on Influenza (PapMV nanoparticles improve mucosal immune responses to the trivalent inactivated flu...

August 20, 2014



Studies from Laval University Yield New Data on Influenza (PapMV nanoparticles improve mucosal immune responses to the trivalent inactivated flu vaccine)

By a News Reporter-Staff News Editor at Vaccine Weekly -- Current study results on Influenza have been published. According to news reporting originating from Quebec City, Canada, by NewsRx correspondents, research stated, "Trivalent inactivated flu vaccines (TIV) are currently the best means to prevent influenza infections. However, the protection provided by TIV is partial (about 50%) and it is needed to improve the efficacy of protection."

Our news editors obtained a quote from the research from Laval University, "Since the respiratory tract is the main site of influenza replications, a vaccine that triggers mucosal immunity in this region can potentially improve protection against this disease. Recently, PapMV nanoparticles used as an adjuvant in a formulation with TIV administered by the subcutaneous route have shown improving the immune response directed to the TIV and protection against an influenza challenge. In the present study, we showed that intranasal instillation with a formulation containing TIV and PapMV nanoparticles significantly increase the amount of IgG, IgG2a and IgA in lungs of vaccinated mice as compared to mice that received TIV only. Instillation with the adjuvanted formulation leads to a more robust protection against an influenza infection with a strain that is lethal to mice vaccinated with the TIV."

According to the news editors, the research concluded: "We demonstrate for the first time that PapMV nanoparticles are an effective and potent mucosal adjuvant for vaccination."

For more information on this research see: PapMV nanoparticles improve mucosal immune responses to the trivalent inactivated flu vaccine. Journal of Nanobiotechnology, 2014;12():19. (BioMed Central - www.biomedcentral.com/; Journal of Nanobiotechnology - www.jnanobiotechnology.com)

The news editors report that additional information may be obtained by contacting G. Rioux, Dept. of Microbiology, Infectiology and Immunology, 'Centre de recherche en Infectiologie', Laval University, 2705 boul, Laurier, Quebec City, PQ G1V 4G2, Canada. Additional authors for this research include C. Mathieu, A. Russell, M. Bolduc, M.E. Laliberte-Gagne, P. Savard and D. Leclerc (see also Influenza).

Keywords for this news article include: Canada, Quebec City, Nanoparticle, Nanotechnology, Viral Vaccines, Influenza Vaccines, Biological Products, Emerging Technologies, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Vaccine Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters